Literature DB >> 15842966

Usefulness of real-time myocardial perfusion imaging to evaluate tissue level reperfusion in patients with non-ST-elevation myocardial infarction.

Grigorios Korosoglou1, Nina Labadze, Evangelos Giannitsis, Raffi Bekeredjian, Alexander Hansen, Stefan E Hardt, Christiane Selter, Roger Kranzhoefer, Hugo Katus, Helmut Kuecherer.   

Abstract

Microvascular integrity is a prequisite for functional recovery in patients who have myocardial infarction after recanalization of the infarct-related coronary artery. In this study, we investigated whether impaired myocardial perfusion is present in patients who have non-ST-elevation myocardial infarction and whether the extent and time course of myocardial tissue reperfusion as assessed by myocardial contrast echocardiography (MCE) are related to functional recovery. Consecutive patients (n = 32) who presented with a first non-ST-elevation myocardial infarction were included in our study. MCE was performed on admission, 1 to 4 hours after angioplasty, and at 24 hours, 4 days, and 4 weeks of follow-up. Contrast images were analyzed visually and quantitatively. Myocardial blood flow was estimated by calculating the product of peak signal intensity and the slope of signal intensity increase. Improvement of wall motion on follow-up echocardiograms after 4 weeks served as a reference for functional recovery of impaired left ventricular function. Of 496 segments available for analysis, 128 (26%) were initially dysfunctional and 96 (75%) recovered at 4 weeks of follow-up. Myocardial tissue reperfusion occurred gradually, expanding over the first 24 hours after percutaneous coronary intervention (myocardial blood flow of 0.4 +/- 0.3 initially, 0.6 +/- 0.4 at 24 hours, and 1.6 +/- 0.7 dB/s at 4 weeks of follow-up, p <0.001). Extent of tissue reperfusion was closely related to grade of improvement of global ejection fraction (r2 = 0.76, p <0.001). MCE predicted functional recovery with a sensitivity of 81%, a specificity of 88%, and accuracy of 83% on a segmental level. Thus, impaired microvascular integrity is suggested by MCE in patients who present with non-ST-elevation myocardial infarction. Improvement of regional tissue perfusion after revascularization is closely related to functional recovery. This information may aid risk stratification and allow monitoring of the effectiveness of reperfusion therapy in these patients.

Entities:  

Mesh:

Year:  2005        PMID: 15842966     DOI: 10.1016/j.amjcard.2004.12.055

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Usefulness of myocardial parametric imaging to evaluate myocardial viability in experimental and in clinical studies.

Authors:  G Korosoglou; A Hansen; R Bekeredjian; A Filusch; S Hardt; D Wolf; D Schellberg; H A Katus; H Kuecherer
Journal:  Heart       Date:  2005-06-06       Impact factor: 5.994

2.  Vessel masking improves densitometric myocardial perfusion assessment.

Authors:  Tamás Ungi; Zsolt Zimmermann; Erika Balázs; András Lassó; Imre Ungi; Tamás Forster; András Palkó; Attila Nemes
Journal:  Int J Cardiovasc Imaging       Date:  2008-10-04       Impact factor: 2.357

Review 3.  Contrast echocardiography for detection of myocardial perfusion abnormalities : A clinical perspective.

Authors:  N Karogiannis; R Senior
Journal:  Herz       Date:  2017-05       Impact factor: 1.443

4.  Evaluation of the effect of myocardial perfusion after percutaneous coronary intervention in coronary artery disease by using intracoronary myocardial contrast echocardiography and two other angiographic techniques.

Authors:  Hong Wang; Lan Huang; Jun Jin; Yaoming Song; Zhaohua Geng; Xuejun Yu; Jun Qin; Gang Zhao; Yunhua Gao; Zheng Liu; Li Yang
Journal:  Front Med China       Date:  2007-02-01

Review 5.  Use of contrast echocardiography in intensive care and at the emergency room.

Authors:  Bernard Cosyns; Bram Roossens; Sophie Hernot; Philippe El Haddad; Herve Lignian; Luc Pierard; Patrizio Lancellotti
Journal:  Curr Cardiol Rev       Date:  2011-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.